The AstraZeneca share price has smashed the FTSE 100 in 2018. I say it could do so again in 2019

Rupert Hargreaves explains why he thinks AstraZeneca plc (LON:AZN) will continue to outperform the FTSE 100 (INDEXFTSE: UKX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are only a few stocks in the FTSE 100 that have outperformed the blue-chip index this year. AstraZeneca (LSE: AZN) is one of these. Year-to-date, the stock is up 21.3%, excluding dividends, compared to a loss of 6.4% for the FTSE 100. 

Including dividends, Astra’s performance is even more impressive. The stock is up 23.4% in 2018, compared to a loss of 5.4% for the UK’s leading blue-chip index, a total outperformance of 28.8%. 

You might think that after this market-beating performance in 2018, shares in Astra are set to lag the FTSE 100 in 2019. However, reckon the firm will continue to lead the index higher next year. Here’s why. 

Pushing ahead

Astra has come a long way since 2014 when US drugs giant Pfizer tried to acquire the business for £69.4bn. When management rejected the £55-a-share deal, a 45% premium over the share price at the time, investors analysts were sceptical that it was making the right decision. 

Four years on, and it looks as if management did chose the right path. While the buyout might have delivered a quick return for investors, if you’d invested £10,000 in Astra back in 2014, today it would be worth over £20,000, including reinvested dividends. In other words, shareholders have benefited significantly from the deal not going ahead. 

But what does the future hold for the company? Well, 2018 has been somewhat of an inflection year for the firm. After a wave of new treatment launches, for the first time in four years, the group’s sales increased by 9% in the third quarter. On a statutory basis, total revenue for the nine months fell 6% to $15.7bn. 

I think this is a sign of things to come. Third quarter sales momentum is set to continue “into the fourth quarter and beyond,” according to Mark Mallon, Astra’s executive vice-president of global product. New medicines and growth in emerging markets have helped offset sales declines in the group’s legacy product portfolio, which includes the former blockbuster blood pressure drug Crestor. Sales of Crestor continue to decline as the product suffers from growing generic competition. 

City analysts expect this top-line growth to start benefitting Astra’s bottom line this year. The City has pencilled in earnings per share (EPS) of $3.41 for 2018, up 55.7% year-on-year. EPS are expected to expand further in 2019, growing just under 13% to $3.83. 

Investors returning 

In my opinion, this earnings growth should convince more investors to return, as the company proves that its recovery is well and truly underway. 

What’s more, as earnings expand, Astra’s dividend cover is set to rise to 1.4 times next year. For four of the past five years, the dividend hasn’t been wholly covered by EPS.

With Astra’s income credentials improving, and earnings expanding again, I think it’s highly likely that the stock will continue to outperform the market in 2019. And if it doesn’t, investors are still set to receive a dividend yield of 3.6%, significantly above the interest rate on offer from most savings accounts today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Investing Articles

This 10.6% yielder beats every dividend share on the FTSE 100. Can it last?

Harvey Jones couldn't resist the double-digit yield on offer from this FTSE 100 stock. Now he'd like to get some…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

With the FTSE 100 flying, I love the look of this company

The FTSE 100 index has been in rally mode over the last few months, but I think one of it's…

Read more »

Investing Articles

17% of my Stocks and Shares ISA is invested in these 2 UK shares

Stephen Wright looks to focus on investments in companies that have strong competitive advantages. And two UK shares stand out…

Read more »

Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA into Lloyds shares

Harvey Jones bought Lloyds shares last year and is kicking himself for failing to buy even more of them. The…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Apple is still my favourite company in the S&P 500, here’s why

Apple recently unveiled a lot of new software at a developer conference. Here's why the tech giant is still my…

Read more »

Investing Articles

5 great value UK companies I’d buy in a Stocks and Shares ISA and aim to hold for decades 

Harvey Jones is getting to work on his Stocks and Shares ISA. He thinks these five firms have solid income…

Read more »

Value Shares

Are GSK shares a bargain after falling 11%?

GSK shares have taken a hit in recent weeks due to Zantac uncertainty. Here, Edward Sheldon looks at whether they’re…

Read more »

Investing Articles

Nearing £5, could the Rolls-Royce share price hit £6?

The Rolls-Royce share price has soared in the past year. Our writer thinks there could be a strong runway ahead…

Read more »